Novartis’ Secukinumab Sails Through Advisory Panel, Bodes Well For IL-17 Class
This article was originally published in The Pink Sheet Daily
Executive Summary
Unanimous advisory committee vote positions Novartis’ secukinumab to beat Lilly and Amgen/AstraZeneca competitors to market; panel supportive of Novartis’ preferred dose, letting other dosing issues be further explored post-market.